🇺🇸 Tacrolimus, Mylan in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Creatinine Increased — 2 reports (15.38%)
  2. Cytomegalovirus Infection — 2 reports (15.38%)
  3. Transplant Rejection — 2 reports (15.38%)
  4. Acute Hepatic Failure — 1 report (7.69%)
  5. Acute Kidney Injury — 1 report (7.69%)
  6. Adenovirus Infection — 1 report (7.69%)
  7. Alanine Aminotransferase Increased — 1 report (7.69%)
  8. Aortitis — 1 report (7.69%)
  9. Back Pain — 1 report (7.69%)
  10. Bacteriuria — 1 report (7.69%)

Source database →

Other Immunology approved in United States

Frequently asked questions

Is Tacrolimus, Mylan approved in United States?

Tacrolimus, Mylan does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Tacrolimus, Mylan in United States?

University of Cincinnati is the originator. The local marketing authorisation holder may differ — check the official source linked above.